Successful Balloon Mitral Valvuloplasty in 21-week Pregnant Patient with Severe Mitral Stenosis: A Case Report and Literature Review by Silitonga, Cynthia Yosephine et al.
ACI (Acta Cardiologia Indonesiana) (Vol.5 No.1): 80-89 
80 
 
Successful Balloon Mitral Valvuloplasty in 21-week Pregnant 
Patient with Severe Mitral Stenosis: A Case Report and 
Literature Review 
 
Cynthia Yosephine Silitonga*, Nahar Taufiq, Budi Yuli Setianto 
 
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas 
Gadjah Mada – Dr. Sardjito General Hospital, Yogyakarta, Indonesia 
 
*Corresponding author: 
Cynthia Yosephine Silitonga, MD, - email: cynthiaysilitonga@yahoo.co.id 
Department  of  Cardiology  and  Vascular  Medicine,  Faculty  of  Medicine, Public Health and Nursing, 
Universitas  Gadjah Mada – Dr. Sardjito  Hospital    
Jalan  Farmako  Sekip Utara,  Yogyakarta,  Indonesia  55281  
 
Manuscript submitted: October 16, 2018; Revised and accepted: March 1, 2019 
ABSTRACT 
Mitral stenosis is the most common manifestation of rheumatic heart 
disease. Hemodynamic changes during pregnancy increase the burden of the 
heart in pregnant women with cardiac abnormalities.  A 33 years old woman, 
G3P1A1 is 21 weeks pregnant came to our hospital with a shortness of breath 
during daily activity, which was worsened since 3 months of pregnancy. The 
patient has been diagnosed with severe mitral stenosis. The results of 
echocardiography examination was left atrial dilatation, normal global function 
and left ventricular with ejection fraction 51%, severe mitral stenosis Wilkin Score 
8 with Mitral Valve area 0.53 cm2 and Mitral Valve Gradient 33 mmHg. 
Subsequently, Balloon Mitral Valvuloplasty was successfully performed. During 
and after the procedure there was no complication. The fetus was considered in 
stable condition.  
Keywords: severe mitral stenosis; balloon mitral valvuloplasty; pregnant 
 
INTISARI 
Mitral stenosis merupakan manifestasi paling umum dari penyakit jantung 
rematik. Perubahan hemodinamik selama kehamilan semakin menambah beban 
jantung pada pasien hamil dengan kelainan jantung. Seorang Wanita, usia 33 
tahun, G3P1A1, hamil 21 minggu datang ke Rumah Sakit Dr. Sardjito dengan 
keluhan sesak nafas saat aktifitas sehari-hari.Pasien telah didiagnosis dengan 
mitral stenosis. Hasil ekokardiografi menunjukkan dilatasi atrium kiri, fungsi 
global dan segmental ventrikel kiri baik dengan ejeksi fraksi 51%, mitral stenosis 
severe Wilkin Score 8 dengan Mitral Valve Area 0,53 cm2 dan Mitral Valve 
Gradient 33 mmHg. Pasien dilakukan Balloon Mitral Valvuloplasty (BMV) di 
RSUP Dr. Sardjito dan berhasil baik. Selama dan sesudah tindakan tidak 
didapatkan komplikasi. Keadaan janin pasca tindakan dinilai baik.  
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INTRODUCTION 
Mitral stenosis (MS) is the 
most common manifestation of 
rheumatic heart disease.1 
Hemodynamic changes during 
pregnancy increase the burden of 
the heart in pregnant women with 
cardiac abnormalities. Although the 
prevalence of cardiovascular 
complications in pregnancy is low, 
reaching one to three percent, but it 
is responsible for 10-15%for 
maternal mortality.2 
In 20 countries worldwide 
where rheumatic heart disease 
remains endemic, the age-
standardized prevalence is 
estimated at >1% and greatest in 
women of childbearing age.3 In India 
the rheumatic heart disease 
contributes to approximately 69% of 
cardiac disorders seen in 
pregnancy.3 The maternal mortality 
rate in women with cardiac disease 
is as high as 7%, and morbidity rate 
higher than 30% during pregnancy.4 
Mitral stenosis (MS) due to 
rheumatic heart disease is the most 
common cause of maternal death 
from cardiac cause wordwide. The 
rate of maternal complications is 
proportional to severity of MS and 
ranges from 26% with mild MS to 67 
% with severe MS.1 The fetal 
morbidity rate in developed countries 
also rises with severity of MS from 
14% in pregnant patients with mild 
MS, 28% in MS moderate and 33% 
in severe MS. Moderate and severe 
MS is rarely tolerable during 
pregnancy.2 
Although MS is 
asymptomatic, the cardiac 
decompensation symptoms may 
worsen with increasing gestational 
age and delivery, provides both 
maternal and fetal morbidity and 
mortality. Interventions are 
sometimes obligatory. Percutaneous 
intervention in pregnant women has 
been a concern for medical 
practitioners and patients related to 
radiation exposure. However, 
balloon mitral valvulopasty (BMV) is 
more recommended than surgery in 
severe MS pregnant patients with 
decompensated symptoms that are 
not resolved with medical therapy. 
We report a BMV procedure in 21 
weeks pregnant women with severe 
mitral stenosis. 
CASE PRESENTATION 
 A 33 years old woman, 
G3P1A1 is 21 weeks pregnant came 
to Dr. Sardjito Hospital with a 
shortness of breath during daily 
activity, which was worsened since 3 
months of pregnancy. The 
complaintwas accompanied by 
swelling on both legs. She felt more 
comfortable to sleep with half-sitting 
position. Chest pain was denied. 
Patients did not complain of 
diarrhea, pain during urination, fever, 
dizziness nor palpitation. History of 
high blood pressure and high 
cholesterol is also denied, no 
previous history of heart attacks, 
diabetes mellitus, smoking, nor  
heart attacks in family member.  
The complaints began since 
7 years ago when she was pregnant 
for the first time. She began to feel 
shortness of breath and fainted 
couple times. She then had a 
miscarriage at 12 weeks gestation 
and had done curettage. She was 
told she had vascular heart disease 
and took medication and control with 
routine therapy of digoxin, 
furosemide and potassium 
supplementation. Three years later 
she had second pregnancy, with a 
history of spontaneous labor through 
vacuum extraction at 38 weeks 
gestation. The baby was born crying 
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instantly, with body weight 2900 
grams. 
On physical examination we 
found that she was compos mentis. 
The blood pressure was 110/70 
mmHg, pulse rate was 98 times per 
minute regularly, respiration rate was 
24 times per minute, temperature 
was 36.2º C, peripheral saturation 
was 95%. Conjunctiva was not 
anemic, sclera not jaundice. There 
was elevated jugular venous 
pressure of 5+3 cm H2O. 
Examination of the lung showed 
vesicular voices no rhonchi in both 
lungs. Cardiac examination was 
minimal cardiomegaly with widening 
the right heart margin, palpable ictus 
cordis between the ribs in the left 
midclavicula linea and right heart 
border at the lateral finger of the 
paralternal dextra line. Normal S1 
and normal S2 sound, middiastolic 
murmur 2/4 on apex. Abdominal 
examination showed uterine fundus 
was at height of five fingers below 
the navel, normal peristaltic. Liver 
and spleen were not palpable. 
Examination of the etremities 
showed warm extremities with no 
oedema. ECG examination was 
sinus rhythm, 72 times per minute, 
Right axis deviation (RAD), Left 
Atrial dilatation, and Right ventricular 
strain. 
Laboratory examination was 
Hb 12.8 mg/dL,37% hematocryte 
37%, leukocyte 12.33 mm3, platelets 
267 mm3, creatinine 0.57 mg/dL and 
blood urea nitrogen (BUN) 7.7 
mg/dL, SGOT 18 U/L, SGPT 17 U/L, 
blood sugar 92 mg/dl, sodium 134 
mmol/L, potassium 3.71 mmol/L, 
chloride 98 mmol/L. 
The result of 
echocardiography examination was 
left atrial dilatation, normal global 
function and left ventricular with 
ejection fraction (EF) 51%, no 
regional wall motion abnormality, 
normal left ventricular diastolic 
function, normal right ventricular 
systolic function, severe MS Wilkin 
Score 8 with Mitral valve area (MVA) 
0.53 cm2 and mitral valve gradient 
(MVG) 33 mmHg. Medium-severe 
regurgitation tricuspid (TR) with 
moderate pulmonary hypertension 
(Figure 2). 
 
 
Figure 1. Electrocardiogram showed sinus rhythm 72 bpm, RAD, left atrial dilation and RV strain 
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Figure 2. Transthoracic Echocardiography showed Severe Mitral Stenosis with MVA 0.53 cm
2
 and 
Mitral Valve Gradient (MVG) 33 mmHg. 
 
 
Figure 3. Transoesophageal Echocardiography Post procedure showed MVA 1.51 cm
2 
and MVG 
decreased 7 mmHg  
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The patient was diagnosed 
with congestive heart failure 
functional class II-III et causa 
diagnosis anatomy of MS severe, 
diagnosis etiology of rheumatic heart 
disease in patient G2P1A1 21 weeks 
gestation age. 
The BMV procedure was 
performed at Dr. Sardjito Hospital. 
During and after the procedure there 
was no complication. The fetus was 
considered in stable condition. 
Echocardiography post procedure 
was MVG decreased 7 mmHg and 
MVA 1.51 cm2. Patient then 
discharged from the hospital with 
therapy furosemide 40 mg q.i.d., 
digoxin 1 tablet q.i.d., potassium 
supplemetation 1 tablet q.i.d. and 
warfarin 2 mg q.i.d. 
 
DISCUSSION 
 
During normal pregnancy, 
the women’s cardiovascular system 
will adapt to various hemodynamic 
changes such as increased heart 
rate, blood volume and vasodilation.5 
These hemodynamic changes in the 
women’s body occured from the time 
of conception to birth to meet the 
metabolic needs of the fetus.6 
Hemodynamic changes during 
pregnancy started with the 
decreasing of systemic vascular 
resistance. Decreased vascular 
resistance is mediated by 
prostaglandin and increased 
production of nitric oxide. Nitric oxide 
is a vasodilator produced by the 
placental endothelium. This 
decrease in vascular resistance is 
accompanied by compensatory 
reaction by the kidneys to increased 
plasma volume and cardiac output.5 
During normal pregnancy 
there is an increase of 20%-30% 
mass of erythrocytes and 30-50% of 
plasma volume. These changes lead 
to increase of blood volume with 
relative anemia. The pulse rate 
increases and there is a decrease in 
pulmonary and systemic vascular 
resistance, as well as a decrease in 
blood pressure. These 
hemodynamic changes result in 
increased cardiac output in early 
pregnancy until the 32nd week of 
pregnancy.7 
The increasing of cardiac 
output during pregnancy will be 
redistributed selectively. Blood flow 
to the uterus will increase up to 10 
times compared with non-pregnant 
conditions. Likewise there will be 
increased perfusion to the kidney, 
breast and skin. However, there is 
no autoregulation of increased 
cardiac output so perfusion to the 
uterus decreases if there is a 
decrease in blood flow from the 
mother as in the supine position.6 
Pregnancy is also associated 
with hypercoagulatory status with 
decreased tissue plasminogen 
activator (TPA) and increased fast-
acting tPA inhibitors and factors V, 
VII, VII, IX, X XII and von Willebrand. 
Protein S increased and increased 
resistance to activated protein C. In 
pregnant women with mitral 
stenosis, hemodynamic changes 
during pregnancy such as increased 
cardiac output and decreased 
vascular resistance will result in a 
greater pressure gradient between 
the left atrium and left ventricle and 
increased blood flow through the 
mitral valve. This condition can 
cause dilatation of the left atrium and 
pulmonary venous hypertension 
leading to pulmonary arterial 
hypertension and increased right 
ventricular overload so that the 
patient will suffer clinical 
decompensated heart failure. This 
condition especially manifest in the 
third trimester where plasma volume 
and heart rate are at their 
maximum.8 
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Ideally women with MS 
should do counseling and 
multidisciplinary education before 
deciding to get pregnant. There are 
several approaches to estimating the 
risk of cardiovascular complications 
in pregnant women. One of them is 
CARPREG score:  
 Previous history of 
cardiac disease (heart 
failure, transient 
ischaemic attack, stroke, 
arrhythmia) 
 Decreased of capacity 
function (NYHA>II) or 
cyanosis before 
pregnancy 
 Left ventricular systolic 
function decreased 
(ejection fraction <40%) 
 Left heart obstruction 
(mitral valve area <2 cm2, 
aortic valve area 
<1.5cm2) 
The presence of one 
predictor has possible complication 
in the mother up to 27% and the 
presence of more than one predictor 
up to 75%. The patient has two 
predictorswhich are left heart 
obstruction, and the decrease of 
capacity function with increase with 
the age of pregnancy. Maternal 
complications are a worsening of 
symptoms of heart failure such as 
progresssion manifestation of heart 
failure and pulmonary edema. The 
Task Force recommends that 
maternal risk assessment is carried 
out according to the modified World 
Health Organization (WHO) risk 
classification. The patient was WHO 
class IV because of severe mitral 
stenosis and should be advised 
against pregnancy but she was 
decided to be pregnant. In this 
situation monthly or bimonthly review 
is needed. Maternal mortality rates 
vary from zero to three percent. 
Complications in the fetus or infant 
such as premature birth, small birth 
and respiratory distress. Preterm 
birth rates in mothers with MS were 
20-30% and intrauterine growth 
disorders up to 5-20%.9 Fetal and 
neonatal mortality rates in mothers 
with mitral stenosis reach 4%.8 
All patients with moderate-
severe MS although asymptomatic 
should be counselledagainst 
pregnancy and intervention should 
be performed before pregnancy. 
Treatment options for mitral stenosis 
in pregnant women are 
medicamentous and intervention 
strategy such as correction with 
surgery or percutaneous 
intervention. Medical therapy 
includes limiting the activity, use of 
diuresis and beta blocker to reduce 
cardiac decompensation symptoms. 
Patients with atrial fibrillation, left 
atrial thrombus and embolism history 
are recommended for anticoagulant 
therapy.9 
Intervention can be either 
percutaneous or surgical. Ideally 
performed after 20 weeks of 
gestation with some consideration of 
pregnant women with NYHA III/IV 
with and or an estimated pulmonary 
artery pressure greater than 50 
mmHg despite optimal medical 
therapy. In percutaneous procedure 
should consider the minimum 
radiation dose.9,10  
The mortality rate of heart 
surgery in pregnant women is 
relatively high at 6 percent. This 
condition is due to surgical 
procedures performed in emergency 
situations and almost equal to the 
mortality rate of emergency cardiac 
surgery in general. However, 
maternal heart surgery with 
Cardiopulmonary Bypass (CBP) also 
gives a high fetal mortality rate up to 
33%. Increased gestational age and 
increased hypothermia are factors 
known to increase fetal morbidity 
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during CPB.11 Thus surgical action is 
indicative in patients with symptoms 
not improving with aggressive 
medicament and percutaneous 
contraindications.12 Contraindication 
of BMV are in patients with severe 
mitral regurgitation or if there is a left 
atrial thrombus.13 
The maternal mortality rate 
for percutaneous valvulopathic 
procedure as low as 0.2% with a 
fetal mortality rate about 2% 
including elective termination. 
Percutaneous intervention success 
rate of 98%.12 Percutaneous 
valvuloplasty procedure may 
increase the NYHA class to 
functional class I or II.1 However, 
one of disadvantage of 
percutaneous procedure is exposure 
to radiation. If the patient is 
diagnosed with MS early in 
pregnancy, the procedure should 
wait until the 12-14 weeks of 
gestation to prevent exposure to 
radiation during the process of 
organogenesis. If there are 
indications of action at age 20 
weeks, as much as possible until the 
age of 26 to 30 weeks to prevent the 
possibility of premature birth.12 
According to the ESC Guideline in 
2011 if percutaneous intervention is 
absolutely necessary, the best time 
for intervention is after the fourth 
month in the second trimester, when 
the organogenesis is complete, the 
fetal thyroid is still inactive and the 
uterine volume is small enough that 
the chest to the uterus is relatively 
distant.9  
Exposure to radiation to the 
fetus during pregnancy is depending 
on radiation dose and age at 
exposure. Radiation exposure can 
lead to inhibited growth of 
intrauterine, microchepalus, 
leukemia and various other 
malignancies. There is no reference 
value of radiation exposure in which 
an increased risk of congenital 
malformation occurs. The general 
principle in using radiation in 
pregnant women is to use minimal 
radiation or ALARA (as low as 
reasonably achievable). Up to now 
less than 50 mGy radiation exposure 
has not been shown to cause 
congenital malformations, intellectual 
decline, growth disorders or 
abortion. However, radiation 
exposure of more than 50 mGy in 
fetuses over 14 days is thought to be 
associated with congenital 
malformations, impaired fetal and 
intellectual growth9. Documented 
doses of radiation causing 
intellectual disability are 610 mGy.14 
The radiation exposure in 
various imaging procedures is not 
high. In radiation exposure to the 
fetus up to 1 mGy, the risk of cancer 
in children is very low. Termination 
of pregnancy simply because it has 
exposure to diagnostic radiation is 
not recommended.14 During the 
procedure of BMV, the patient was 
exposed to radiation with a dose of 
408 mGy, above the estimated 
treshold dose. However, only a small 
amount of the radiation delivered on 
the thorax reaches the fetus.8 
Although the procedure is effective, 
long term effects of foetal exposure 
to radiation during the use of 
fluoroscopy is a matter of concern 
and needs to be studied further. 
Studies show that infants of mothers 
who underwent BMV in the second 
and third trimester of pregnancy 
have normal long-term growth and 
development. However, because of 
the small sample size, the 
teratogenic effect of the ionising 
radiation cannot be totally excluded. 
Childhood malignancy is extremely 
rare and a study of this size cannot 
address this issue. Given the rarity 
of childhood malignancy, the 
benefits of the BMV probably 
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outweight the possible increased risk 
of childhood malignancy.15 Beyond 
doubt it is now clear that radiation 
exposure after 20 weeks of gestation 
is unlikely to produce any form of 
major abnormalities. Most of the 
centres take only short time.  
The dangers of radiation rays 
can be minimized by delaying the 
action during the process of 
organogenesis, using a curtain in the 
abdominal and pelvic areas, 
avoidance of left ventricular 
angiography, using echo 
cardiography as a guide during the 
action, using Inoue balloon 
technique and performed by 
experienced experts to reduce 
radiation exposure time.16 Use of the 
abdominal cavity is recommended, 
although it only reduces the dose of 
exposure to the fetus by 2%, 
because the abdominal curtain can 
not prevent the spread of intra-
abdominal radiation.10 In the patient 
is subjected to a screen on the 
abdominal area to the pelvis, both 
front and rear. 
Percutaneous BMV still have 
other risk during procedures other 
than radiation hazards, mitral 
regurgitant complications and 
cardiac tamponade which is 
hemodynamic changes. The 
haemodynamic risk is due to 
hypotension of the inferior 
compression of the glass vein when 
the mother is in a supine position 
during the procedure and the old 
balloon inflation. This causes fetal 
distress.17 Because of the risk of 
complications, percutaneous mitral 
commissurotomy should not be 
performed in asymptomatic mitral 
stenosis patients.9 
 Study by Lee et al. (1993) 
and Sivadasanpillai et al. (2005) 
showed that children born to 
mothers who underwent BMV during 
pregnancy had normal development 
and growth. This patient was done 
BMV procedure because it proved 
relatively safe with low mortality and 
morbidity rates for both mother and 
fetus.15,18 Gulraze et al. (2014) 
studied the seventeen years 
outcome of 23 cases of mitral 
balloon valvuloplasty during 
pregnancy. The children born of 
subsequent pregnancies exhibited 
normal pysical ad mental 
development.1  
 
CONCLUSION 
 
A 33 years old woman came 
to Dr. Sardjito Hospital with 
shortness of breath during daily 
activities. Complaints are 
accompanied by swelling on both 
legs. The patient has been 
diagnosed with severe mitral 
stenosis. Patients are known to be 
pregnant with the third child, 21 
weeks pregnant with history of first 
child miscarriage. The results of 
echocardiography showed MS 
severe Wilkin Score 8 with Mitral 
Valve area (MVA) 0.53 m2 and 
mitral Valve Gradient (MVG) 33 
mmHg, medium-severe regurgitation 
tricuspid (TR) with moderate 
pulmonary hypertension. The patient 
had done BMV with 
Echocardiography post procedure 
was MVG decreased 7 mmHg and 
MVA increased 1.51 cm2. 
Percutaneous procedure 
BMV in pregnant patients has been 
a concern to both medical worker 
and patients related to radiation 
exposure. However, BMV is more 
recommended than surgical 
procedures in pregnant women with 
severe MS with decompensated 
manifestation that are not resolved 
with medical therapy.  
The maternal and fetal 
mortality rate for percutaneous 
valvulopathic procedure is low with 
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high success rate. The dangers of 
radiation beam can be minimized by 
delaying the action during the 
process of organogenesis, using a 
curtain in the abdominal and pelvic 
areas, avoidance of left ventricular 
angiography, using 
echocardiography as a guide during 
the procedure, using Inoue balloon 
technique and performed by 
experienced experts to reduce 
radiation exposure time. 
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